Notícias e Atividades da Norgine France

Norgine France pertence à Norgine. Norgine tem presença direta em 3 países.

Norgine possui 3 subsidiárias incluindo Norgine France, Norgine UK e Norgine Ventures.

Eles estão dentro:

• Farmacêutica75%
• Fundo25%

Veja o organograma con seus 7 executivos principais

Biografias mais buscadas da Norgine France

• Cyril Tavier, General Manager
• Sandrine Marie, Commercial Management Controller and Customer Rela...
• Stephanie Magnier-Abraham, Regulatory Affairs Director and Head Ph...

Recentes movimentos de executivos em Norgine

• Janneke Van Der Kamp ingressará na Companhia como Chief Executive Officer em 1 de jan. de 2025  (Notícia publicada em 4 de outubro de 2024).
• Christopher Bath, Chief Executive Officer, deixou a Companhia  (Notícia publicada em 4 de outubro de 2024).

Criar um alerta
para seguir os movimentos de executivos da Norgine France.

Norgine possui 1.828 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Chimerix and Chimerix have merged  (publicado em 22 de abril de 2025)..
• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Seth Harrison - Chairman and Director da Braeburn Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Norgine France

• Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma - Norgine
• Norgine receives positive CHMP opinion recommending approval of NPJ5008 (dantrolene sodium hemiheptahydrate) for the treatment of malignant hyperthermia - Norgine
• Norgine Announces Appointment of New CEO Janneke van der Kamp - Norgine
• Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand - Norgine
• Pedmarqsi® (anhydrous sodium thiosulfate) recommended by NICE for patients 1 month to 17 years of age in England and Wales for the prevention of cisplatin-induced hearing loss - Norgine
• European study highlights need to improve the quality of conversations about induction of labour (IoL) in  clinical settings - Norgine
• Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer - Norgine
• NORGINE LAUNCHES ZIVEREL® IN AUSTRIA, BELGIUM, LUXEMBOURG AND SWITZERLAND - NorgineNORGINE LAUNCHES ZIVEREL® IN AUSTRIA, BELGIUM, LUXEMBOURG AND SWITZERLAND - Norgine
• LYMPHOSEEK®▼ (99mTc-tilmanocept) LAUNCHES IN EUROPE - NorgineLYMPHOSEEK®▼ (99mTc-tilmanocept) LAUNCHES IN EUROPE - Norgine
• NORGINE B.V. ACQUIRES AZANTA A/S, STRENGTHENING ITS POSITION AS A LEADING EUROPEAN SPECIALIST PHARMACEUTICAL COMPANY - NorgineNORGINE B.V. ACQUIRES AZANTA A/S, STRENGTHENING ITS POSITION AS A LEADING EUROPEAN SPECIALIST PHARMACEUTICAL COMPANY - Norgine
• View more press releases Close

Redes sociais sobre Norgine France

• Norgine France na Wikipedia, Google News e Yahoo Finance
• Norgine France na LinkedIn, Twitter e YouTube